^
BIOMARKER:

HER-2 expression

i
Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Entrez ID:
HER-2 expression
Endometrial Adenocarcinoma
trastuzumab
Sensitive: A2 - Guideline
HER-2 expression
Breast Cancer
ARX788
Sensitive: B - Late Trials
HER-2 expression
Biliary Tract Cancer
ZW25
Sensitive: B - Late Trials
HER-2 expression
Cholangiocarcinoma
trastuzumab + lapatinib
Sensitive: B - Late Trials
HER-2 expression
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: C2 – Inclusion Criteria
HER-2 expression
Gastric Cancer
trastuzumab
Sensitive: C2 – Inclusion Criteria
HER-2 expression
CRC
fam-trastuzumab deruxtecan-nxki
Sensitive: C2 – Inclusion Criteria
HER-2 expression
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: C2 – Inclusion Criteria
HER-2 expression
Gastric Cancer
A166
Sensitive: C2 – Inclusion Criteria
HER-2 expression
Breast Cancer
lapatinib
Sensitive: C2 – Inclusion Criteria
HER-2 expression
CRC
A166
Sensitive: C2 – Inclusion Criteria
HER-2 expression
HER2 Positive Breast Cancer
A166
Sensitive: C2 – Inclusion Criteria
HER-2 expression
HER2 Positive Breast Cancer
avelumab
Sensitive: C2 – Inclusion Criteria
HER-2 expression
Solid Tumor
fam-trastuzumab deruxtecan-nxki
Sensitive: C2 – Inclusion Criteria
HER-2 expression
Solid Tumor
SBT6050
Sensitive: C2 – Inclusion Criteria
HER-2 expression
GastroEsophageal Cancer
ZW25
Sensitive: C3 – Early Trials
HER-2 expression
Salivary Gland Cancer
ARX788
Sensitive: C3 – Early Trials
HER-2 expression
CRC
ARX788
Sensitive: C3 – Early Trials
HER-2 expression
Biliary Tract Cancer
ARX788
Sensitive: C3 – Early Trials
HER-2 expression
NSCLC
ARX788
Sensitive: C3 – Early Trials
HER-2 expression
Gastric Cancer
ARX788
Sensitive: C3 – Early Trials
HER-2 expression
CRC
panitumumab
Resistant: C3 – Early Trials
HER-2 expression
HER2 Positive Breast Cancer
nivolumab + fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
HER-2 expression
Pancreatic Adenocarcinoma
trastuzumab + erlotinib + gemcitabine
Sensitive: C3 – Early Trials
HER-2 expression
CRC
trastuzumab + lapatinib
Sensitive: C3 – Early Trials
HER-2 expression
Childhood B Acute Lymphoblastic Leukemia
trastuzumab
Resistant: C3 – Early Trials
HER-2 expression
Endometrial Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
HER-2 expression
Gastrointestinal Cancer
pembrolizumab + margetuximab
Sensitive: C3 – Early Trials
HER-2 expression
Salivary Gland Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
HER-2 expression
CRC
cetuximab
Sensitive: C3 – Early Trials
HER-2 expression
Urothelial Cancer
toripalimab + disitamab vedotin
Sensitive: C3 – Early Trials
HER-2 expression
Uterine Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
HER-2 expression
Solid Tumor
pembrolizumab + SBT6050
Sensitive: C3 – Early Trials
HER-2 expression
CRC
trastuzumab + tucatinib
Sensitive: D – Preclinical
HER-2 expression
HER2 Positive Breast Cancer
paclitaxel
Sensitive: D – Preclinical
HER-2 expression
CRC
tucatinib
Sensitive: D – Preclinical
HER-2 expression
Pancreatic Cancer
afatinib
Sensitive: D – Preclinical
HER-2 expression
Solid Tumor
ABL105
Sensitive: D – Preclinical